NASDAQ:FBRX Forte Biosciences Q4 2025 Earnings Report $76.99 0.00 (0.00%) As of 08/27/2026 ProfileEarnings HistoryForecast Forte Biosciences EPS ResultsActual EPS-$1.45Consensus EPS -$1.42Beat/MissMissed by -$0.03One Year Ago EPSN/AForte Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AForte Biosciences Announcement DetailsQuarterQ4 2025Date3/31/2026TimeAfter Market ClosesConference Call DateTuesday, March 31, 2026Conference Call Time7:00AM ETUpcoming EarningsForte Biosciences' Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Forte Biosciences Earnings HeadlinesForte Biosciences, Inc. (NASDAQ:FBRX) Receives Consensus Rating of "Hold" from BrokeragesSeptember 9, 2026 | americanbankingnews.comForte Biosciences Completed Take-Private Merger and DelistingAugust 29, 2026 | theglobeandmail.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 19 at 1:00 AM | Banyan Hill Publishing (Ad)Argenx Completes Acquisition of Forte BiosciencesAugust 27, 2026 | finance.yahoo.comHedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte BiosciencesAugust 11, 2026 | insidermonkey.comForte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRXAugust 11, 2026 | businesswire.comSee More Forte Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Forte Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Forte Biosciences and other key companies, straight to your email. Email Address About Forte BiosciencesForte Biosciences (NASDAQ:FBRX) is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapies for inflammatory and immune-mediated skin diseases. The company’s approach involves using naturally occurring microorganisms and their biological effects to help restore healthy skin function and address disease-related inflammation. Forte’s lead product candidate has been FB-401, a topical live biotherapeutic product based on Roseomonas mucosa, a naturally occurring bacterium found on human skin. The program was developed primarily for the potential treatment of atopic dermatitis, a chronic inflammatory skin condition. Forte has evaluated FB-401 in clinical studies and has used the results to guide its research and development strategy. Founded in 2016, Forte Biosciences is headquartered in Dallas, Texas. The company’s activities have primarily centered on developing therapies for dermatological and immune-related conditions, with its research directed toward patients in markets where these diseases represent significant unmet medical needs.View Forte Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
